Galapagos NV (GLPG)
USD 23.52
(2.08%)
USD 23.52
(2.08%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 327.98 Million EUR | -56.41% |
| 2022 | 760.72 Million EUR | 17.25% |
| 2021 | 648.81 Million EUR | -1.2% |
| 2020 | 656.68 Million EUR | 38.34% |
| 2019 | 474.69 Million EUR | 42.27% |
| 2018 | 333.64 Million EUR | 53.83% |
| 2017 | 216.89 Million EUR | 53.81% |
| 2016 | 141.01 Million EUR | 9.3% |
| 2015 | 129 Million EUR | 22.49% |
| 2014 | 105.32 Million EUR | -0.99% |
| 2013 | 106.37 Million EUR | 17.95% |
| 2012 | 90.18 Million EUR | 2251.07% |
| 2011 | 3.83 Million EUR | -22.05% |
| 2010 | 4.92 Million EUR | -18.77% |
| 2009 | 6.05 Million EUR | -90.12% |
| 2008 | 61.3 Million EUR | 20.23% |
| 2007 | 50.98 Million EUR | 90.21% |
| 2006 | 26.8 Million EUR | 109.74% |
| 2005 | 12.78 Million EUR | 26.57% |
| 2004 | 10.09 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 106.74 Million EUR | 4.24% |
| 2024 Q1 | 102.4 Million EUR | 181.09% |
| 2023 Q3 | 144.56 Million EUR | -7.55% |
| 2023 Q4 | -126.27 Million EUR | -187.35% |
| 2023 Q2 | 156.37 Million EUR | 1.99% |
| 2023 Q1 | 153.32 Million EUR | -31.38% |
| 2023 FY | 331.62 Million EUR | -56.41% |
| 2022 FY | 760.72 Million EUR | 17.25% |
| 2022 Q4 | 223.44 Million EUR | 30.37% |
| 2022 Q1 | 154.58 Million EUR | -0.83% |
| 2022 Q2 | 211.31 Million EUR | 36.7% |
| 2022 Q3 | 171.39 Million EUR | -18.89% |
| 2021 Q2 | 186.52 Million EUR | 13.26% |
| 2021 Q1 | 164.69 Million EUR | 2.97% |
| 2021 Q3 | 141.86 Million EUR | -23.94% |
| 2021 Q4 | 155.87 Million EUR | 9.87% |
| 2021 FY | 648.81 Million EUR | -1.2% |
| 2020 FY | 656.68 Million EUR | 38.34% |
| 2020 Q4 | 159.94 Million EUR | -2.58% |
| 2020 Q3 | 164.17 Million EUR | -13.51% |
| 2020 Q2 | 189.81 Million EUR | 32.96% |
| 2020 Q1 | 142.75 Million EUR | 0.54% |
| 2019 Q2 | 103.1 Million EUR | 19.49% |
| 2019 FY | 474.69 Million EUR | 42.27% |
| 2019 Q3 | 143.3 Million EUR | 38.99% |
| 2019 Q4 | 141.99 Million EUR | -0.91% |
| 2019 Q1 | 86.29 Million EUR | -11.65% |
| 2018 FY | 333.64 Million EUR | 53.83% |
| 2018 Q4 | 97.67 Million EUR | 18.24% |
| 2018 Q3 | 82.6 Million EUR | -0.99% |
| 2018 Q2 | 83.42 Million EUR | 19.28% |
| 2018 Q1 | 69.94 Million EUR | 5.23% |
| 2017 Q1 | 45.21 Million EUR | 6.35% |
| 2017 Q2 | 48.6 Million EUR | 7.5% |
| 2017 Q4 | 66.46 Million EUR | 17.44% |
| 2017 Q3 | 56.59 Million EUR | 16.43% |
| 2017 FY | 216.89 Million EUR | 53.81% |
| 2016 Q1 | 27.51 Million EUR | -17.57% |
| 2016 FY | 141.01 Million EUR | 9.3% |
| 2016 Q3 | 35.34 Million EUR | -0.8% |
| 2016 Q2 | 35.62 Million EUR | 29.48% |
| 2016 Q4 | 42.52 Million EUR | 20.3% |
| 2015 Q1 | 30.12 Million EUR | -2.38% |
| 2015 Q3 | 33.37 Million EUR | 3.91% |
| 2015 Q4 | 33.38 Million EUR | 0.01% |
| 2015 FY | 129 Million EUR | 22.49% |
| 2015 Q2 | 32.12 Million EUR | 6.61% |
| 2014 Q2 | 3.99 Million EUR | 0.0% |
| 2014 Q4 | 30.86 Million EUR | 27.69% |
| 2014 Q3 | 24.17 Million EUR | 504.93% |
| 2014 Q1 | 3.99 Million EUR | -59.23% |
| 2014 FY | 105.32 Million EUR | -0.99% |
| 2013 Q1 | 10.67 Million EUR | -17.53% |
| 2013 Q4 | 9.8 Million EUR | 0.0% |
| 2013 Q3 | 9.8 Million EUR | -8.18% |
| 2013 Q2 | 10.67 Million EUR | 0.0% |
| 2013 FY | 106.37 Million EUR | 17.95% |
| 2012 FY | 90.18 Million EUR | 2251.07% |
| 2012 Q4 | 12.94 Million EUR | 80.82% |
| 2012 Q3 | 7.15 Million EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2011 FY | 3.83 Million EUR | -22.05% |
| 2011 Q4 | - EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2010 FY | 4.92 Million EUR | -18.77% |
| 2010 Q4 | - EUR | 0.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2009 FY | 6.05 Million EUR | -90.12% |
| 2009 Q4 | - EUR | 0.0% |
| 2009 Q2 | - EUR | 0.0% |
| 2008 FY | 61.3 Million EUR | 20.23% |
| 2008 Q4 | - EUR | 0.0% |
| 2007 FY | 50.98 Million EUR | 90.21% |
| 2006 FY | 26.8 Million EUR | 109.74% |
| 2005 FY | 12.78 Million EUR | 26.57% |
| 2004 FY | 10.09 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Akebia Therapeutics, Inc. | 201.11 Million USD | -63.084% |
| Jaguar Health, Inc. | 42.01 Million USD | -680.643% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -93.758% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -477.859% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 81.779% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -288.965% |
| ContextLogic Inc. | 387 Million USD | 15.249% |
| MiMedx Group, Inc. | 229.72 Million USD | -42.773% |
| MEI Pharma, Inc. | 34.78 Million USD | -842.898% |
| AlloVir, Inc. | 180.93 Million USD | -81.275% |
| Novavax, Inc. | 779.12 Million USD | 57.903% |
| Aptorum Group Limited | 10.56 Thousand USD | -3104073.765% |
| Ardelyx, Inc. | 169.93 Million USD | -93.005% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 26.417% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -11819.93% |
| Vaxcyte, Inc. | 468.04 Million USD | 29.923% |
| Precigen, Inc. | 84.18 Million USD | -289.621% |
| Pharming Group N.V. | 225.49 Million USD | -45.455% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -95.432% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -351.984% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -151.788% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -33.786% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -1589.043% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -1249.374% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -1249.374% |
| Bicycle Therapeutics plc | 216.92 Million USD | -51.2% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -43.426% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -962.857% |
| Acelyrin, Inc. | 422.06 Million USD | 22.29% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -766.109% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -784.921% |
| Senti Biosciences, Inc. | 94.7 Million USD | -246.325% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -165.463% |
| AbCellera Biologics Inc. | 275.23 Million USD | -19.167% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -1012.99% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -90.799% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -148.146% |
| Chimerix, Inc. | 93.38 Million USD | -251.205% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -862.262% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -1778.828% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -2257.983% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -547.006% |
| Elevation Oncology, Inc. | 45.44 Million USD | -621.723% |
| Alkermes plc | 996.24 Million USD | 67.078% |
| Fortress Biotech, Inc. | 200.19 Million USD | -63.834% |
| Fortress Biotech, Inc. | 200.19 Million USD | -63.834% |
| Agenus Inc. | 78.18 Million USD | -319.512% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -901.609% |
| Dyadic International, Inc. | 9.15 Million USD | -3483.502% |
| ImmuCell Corporation | 9.61 Million USD | -3310.363% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -1373.9% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -107.831% |
| Lantern Pharma Inc. | 17.87 Million USD | -1734.629% |
| Immix Biopharma, Inc. | 16.14 Million USD | -1931.997% |
| Incyte Corporation | 1.19 Billion USD | 72.45% |
| IO Biotech, Inc. | 91.44 Million USD | -258.679% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -304.613% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -4772.099% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -517.371% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -965.896% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -3781.044% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -287.161% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 13.8% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 18.727% |
| NextCure, Inc. | 67.63 Million USD | -384.922% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -1007.84% |
| Onconetix, Inc. | 34.9 Million USD | -839.591% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -2473.254% |
| Opthea Limited | 191.96 Million USD | -70.856% |
| PDS Biotechnology Corporation | 43.04 Million USD | -661.959% |
| PureTech Health plc | 144.59 Million USD | -126.828% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -299.03% |
| Seer, Inc. | 110.49 Million USD | -196.848% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -2543618.008% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -902.558% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -8220.218% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -1005.003% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -80.907% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -94.725% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -105.265% |
| ChromaDex Corporation | 56.37 Million USD | -481.754% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -1632.722% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -117.879% |
| CRISPR Therapeutics AG | 463.49 Million USD | 29.236% |
| Precision BioSciences, Inc. | 92.46 Million USD | -254.722% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -29.106% |
| Innoviva, Inc. | 132.15 Million USD | -148.185% |
| Summit Therapeutics Inc. | 87.68 Million USD | -274.047% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -364.61% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -250.871% |
| ESSA Pharma Inc. | 32.13 Million USD | -920.682% |
| GlycoMimetics, Inc. | 39.28 Million USD | -734.885% |
| GT Biopharma, Inc. | 13.57 Million USD | -2315.933% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -49.2% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -26.428% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -506.485% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -3200.45% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -26.315% |
| Aptose Biosciences Inc. | 52.35 Million USD | -526.455% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -2176.048% |
| Soligenix, Inc. | 7.79 Million USD | -4107.523% |
| Century Therapeutics, Inc. | 56.07 Million USD | -484.949% |
| Kura Oncology, Inc. | 165.8 Million USD | -97.816% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -186.434% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -3842.625% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -13116.548% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -204.543% |
| Autolus Therapeutics plc | 196.72 Million USD | -66.723% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -287.43% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -181.648% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -1592.137% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -1.936% |
| GRI Bio, Inc. | 11.33 Million USD | -2794.854% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -4548.539% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -150.003% |
| IGM Biosciences, Inc. | 265.59 Million USD | -23.493% |
| INmune Bio, Inc. | 29.89 Million USD | -997.093% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -90.078% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -713.575% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1952.566% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -1983.575% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -428.176% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -205.042% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -18.968% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -8.803% |
| Verastem, Inc. | 92.08 Million USD | -256.182% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -1728.346% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -76.598% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -170.155% |
| Histogen Inc. | 14.27 Million USD | -2198.115% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -1943.769% |
| Surrozen, Inc. | 18.55 Million USD | -1668.124% |
| Organovo Holdings, Inc. | 14.91 Million USD | -2099.041% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -6343.454% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -449.639% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -1178.851% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -597.756% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -4197.049% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -84.122% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -576.988% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -33.87% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -2034.419% |
| Apollomics, Inc. | 54.14 Million USD | -505.813% |
| Amarin Corporation plc | 272.35 Million USD | -20.425% |
| Mesoblast Limited | 5.9 Million USD | -5457.218% |
| Turnstone Biologics Corp. | 78.33 Million USD | -318.682% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -34.354% |
| Synaptogenix, Inc. | 8.31 Million USD | -3845.066% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -2148.643% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -29.61% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -884.057% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -3613.943% |
| Exelixis, Inc. | 1.58 Billion USD | 79.33% |
| Better Therapeutics, Inc. | 38.26 Million USD | -757.213% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -41.343% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 61.648% |
| NLS Pharmaceutics AG | 11.8 Million USD | -2677.888% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -3978.473% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -993.545% |
| Gritstone bio, Inc. | 148.37 Million USD | -121.054% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -376.303% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -1904.784% |
| Avid Bioservices, Inc. | 25.99 Million USD | -1161.683% |
| Insmed Incorporated | 949.26 Million USD | 65.448% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -1990.449% |
| MediWound Ltd. | 18.86 Million USD | -1638.324% |
| OmniAb, Inc. | 83.89 Million USD | -290.949% |
| Alector, Inc. | 248.8 Million USD | -31.827% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -39.981% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -527.714% |
| Zai Lab Limited | 547.47 Million USD | 40.091% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 17.726% |
| Aura Biosciences, Inc. | 84.99 Million USD | -285.908% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -32.714% |
| Immunic, Inc. | 99.22 Million USD | -230.555% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -106.266% |
| Veracyte, Inc. | 357.93 Million USD | 8.366% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 96.362% |
| FibroGen, Inc. | 398.11 Million USD | 17.615% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -2208.142% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -4661.753% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -4502.853% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 89.926% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -1167.681% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -3.615% |
| TG Therapeutics, Inc. | 198.47 Million USD | -65.254% |
| Galecto, Inc. | 35.62 Million USD | -820.614% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -706.083% |
| Fortrea Holdings Inc. | 457.3 Million USD | 28.277% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -504.272% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -1035.768% |
| XBiotech Inc. | 37.51 Million USD | -774.399% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -376.303% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -1488.392% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -130.878% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -231.049% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -196.242% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 65.772% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -1037.067% |
| Vaxxinity, Inc. | 56.05 Million USD | -485.158% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 23.837% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -1370.246% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -195.838% |
| NexImmune, Inc. | 28.16 Million USD | -1064.416% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -5830.032% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -1733.097% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 88.35% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -1188.295% |
| Scopus BioPharma Inc. | 11.71 Million USD | -2699.748% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -158.131% |
| Ainos, Inc. | 12.95 Million USD | -2432.197% |
| Pluri Inc. | 22.48 Million USD | -1359.017% |
| Prothena Corporation plc | 282.4 Million USD | -16.14% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -63.975% |
| Celularity Inc. | 215.05 Million USD | -52.511% |
| Rallybio Corporation | 78.93 Million USD | -315.531% |
| Cue Biopharma, Inc. | 19.54 Million USD | -1578.37% |
| MeiraGTx Holdings plc | 151.07 Million USD | -117.098% |
| Omeros Corporation | 94.75 Million USD | -246.157% |
| Humacyte, Inc. | 23.49 Million USD | -1295.868% |
| Immunocore Holdings plc | 308.04 Million USD | -6.475% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -9575.133% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -277.582% |
| Blueprint Medicines Corporation | 722.86 Million USD | 54.627% |
| CalciMedica, Inc. | 21.81 Million USD | -1403.355% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -339.308% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -104.302% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -91.475% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -11.205% |
| Pulmatrix, Inc. | 22.03 Million USD | -1388.279% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -848.625% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -269.08% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 40.535% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -352.078% |
| Cytokinetics, Incorporated | 173.61 Million USD | -88.92% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -852.924% |
| Nutriband Inc. | 5.73 Million USD | -5620.007% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -652.04% |
| Vor Biopharma Inc. | 126.03 Million USD | -160.233% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 72.419% |
| Evogene Ltd. | 27.79 Million USD | -1080.234% |
| ProKidney Corp. | 151.52 Million USD | -116.462% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -342.18% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -4163.867% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 46.602% |
| CorMedix Inc. | 48.95 Million USD | -569.938% |
| BioLineRx Ltd. | 50.8 Million USD | -545.618% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -117.642% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -761.491% |
| Atai Life Sciences N.V. | 125.78 Million USD | -160.752% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -301.751% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -302.888% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -29.869% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -901.793% |
| MediciNova, Inc. | 10.9 Million USD | -2908.982% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -154.609% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -4418.023% |
| GeoVax Labs, Inc. | 6.02 Million USD | -5346.323% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 31.147% |
| Biomea Fusion, Inc. | 126.13 Million USD | -160.029% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 74.998% |
| Mereo BioPharma Group plc | 35.84 Million USD | -815.091% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -71.641% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -42.632% |
| Absci Corporation | 73.66 Million USD | -345.235% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -1089.134% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -145.518% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -35.441% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -25.163% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -57.691% |
| Allakos Inc. | 196.05 Million USD | -67.293% |
| Imunon, Inc. | 20.31 Million USD | -1514.87% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -189.054% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 11.021% |
| BioAtla, Inc. | 129.68 Million USD | -152.907% |
| NLS Pharmaceutics AG | 11.8 Million USD | -2677.888% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -1970.233% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -286.24% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -685.447% |
| XOMA Corporation | 46.46 Million USD | -605.91% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -195.029% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -130.226% |
| aTyr Pharma, Inc. | 12.97 Million USD | -2427.059% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -216.419% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -89.73% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -28.742% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -776.783% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -3887.774% |
| Akari Therapeutics, Plc | 16.8 Million USD | -1851.607% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -14323.541% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -9.578% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -4774.427% |
| UroGen Pharma Ltd. | 138.88 Million USD | -136.152% |
| Sutro Biopharma, Inc. | 243 Million USD | -34.969% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -4408.647% |
| Orgenesis Inc. | 45.75 Million USD | -616.802% |
| Entera Bio Ltd. | 8.86 Million USD | -3601.885% |
| GH Research PLC | 41.22 Million USD | -695.66% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -1175.817% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -294.913% |
| Xencor, Inc. | 306.97 Million USD | -6.844% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -6548.018% |
| Replimune Group, Inc. | 234.77 Million USD | -39.704% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -1500.726% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -71.008% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -4774.427% |
| Portage Biotech Inc. | 18.19 Million USD | -1702.225% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -4418.023% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -212.485% |
| OncoCyte Corporation | 25.63 Million USD | -1179.35% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -5280.711% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -2762.75% |
| Purple Biotech Ltd. | -22.46 Million USD | 1559.861% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -1890.212% |
| scPharmaceuticals Inc. | 65.17 Million USD | -403.217% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -3780.247% |
| HilleVax, Inc. | 133.34 Million USD | -145.969% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -3088.984% |
| Tharimmune, Inc. | 9.45 Million USD | -3368.846% |
| Genprex, Inc. | 31.06 Million USD | -955.96% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -74.902% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -945.31% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -42774.118% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -5921.514% |
| OKYO Pharma Limited | 8243.57 USD | -3978600.975% |
| Savara Inc. | 15.74 Million USD | -1983.118% |
| Curis, Inc. | 58.35 Million USD | -462.055% |
| Daré Bioscience, Inc. | 33.6 Million USD | -875.879% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -6340.604% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -4296.019% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -1113.778% |
| BeiGene, Ltd. | 3.28 Billion USD | 90.02% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -1544.927% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 34.24% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -113.461% |
| Erasca, Inc. | 141.52 Million USD | -131.752% |
| bluebird bio, Inc. | 240.23 Million USD | -36.529% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -7145.171% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 81.218% |
| DBV Technologies S.A. | 92.16 Million USD | -255.889% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -7145.171% |
| Moderna, Inc. | 6.39 Billion USD | 94.87% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -669.76% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -2183.078% |
| Molecular Templates, Inc. | 63.09 Million USD | -419.863% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -391.727% |
| Travere Therapeutics, Inc. | 472 Million USD | 30.512% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -128.864% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -428.313% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -655.487% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -57.588% |
| MacroGenics, Inc. | 217.21 Million USD | -50.996% |
| RenovoRx, Inc. | 11.39 Million USD | -2778.089% |
| Adicet Bio, Inc. | 152.03 Million USD | -115.727% |
| Prime Medicine, Inc. | 186.63 Million USD | -75.733% |
| Aditxt, Inc. | 25.95 Million USD | -1163.882% |
| Adagene Inc. | 41.83 Million USD | -684.07% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -4386.766% |
| Quantum-Si incorporated | 111.65 Million USD | -193.74% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -90.857% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -2149.912% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -815.602% |
| SciSparc Ltd. | 9.01 Million USD | -3539.851% |
| Vericel Corporation | 142.04 Million USD | -130.912% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -3688.838% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -1320.559% |
| Generation Bio Co. | 144.46 Million USD | -127.032% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -295.022% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -279.351% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -10.911% |
| Invivyd, Inc. | 205.75 Million USD | -59.407% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -354.534% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -3397.221% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -335.84% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -3088.364% |
| 2seventy bio, Inc. | 289.88 Million USD | -13.143% |
| ADMA Biologics, Inc. | 66.58 Million USD | -392.577% |
| Clene Inc. | 41.07 Million USD | -698.546% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -2460.821% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -498.56% |
| GeoVax Labs, Inc. | 6.02 Million USD | -5346.323% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 6.835% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -792.919% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -872.447% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -216.278% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -906.435% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -92.619% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 57.278% |
| Evaxion Biotech A/S | 22.27 Million USD | -1372.775% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -141.978% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -39.639% |
| Trevena, Inc. | 38.41 Million USD | -753.844% |
| Surrozen, Inc. | 18.55 Million USD | -1668.124% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -310.266% |
| Cingulate Inc. | 22.75 Million USD | -1341.119% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 4477.83% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -634.294% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -3883.354% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -219.806% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 56.505% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -428.381% |
| Clearmind Medicine Inc. | 8.74 Million USD | -3652.132% |
| Kronos Bio, Inc. | 128.11 Million USD | -156.004% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -290.126% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -11082.703% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -225.297% |
| Statera Biopharma, Inc. | 28.82 Million USD | -1037.678% |
| ImmunityBio, Inc. | 362.87 Million USD | 9.614% |
| Korro Bio, Inc. | 84.53 Million USD | -287.994% |
| Kineta, Inc. | 21.15 Million USD | -1450.326% |
| BioVie Inc. | 31.95 Million USD | -926.557% |
| Codexis, Inc. | 66.51 Million USD | -393.08% |
| Celularity Inc. | 215.05 Million USD | -52.511% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -44.729% |
| Celcuity Inc. | 66.23 Million USD | -395.222% |
| Virax Biolabs Group Limited | 6.54 Million USD | -4909.681% |
| Cibus, Inc. | 320.3 Million USD | -2.398% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -662.76% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -869.114% |
| IN8bio, Inc. | 30.33 Million USD | -981.145% |
| Kodiak Sciences Inc. | 277.32 Million USD | -18.27% |
| Annexon, Inc. | 143.72 Million USD | -128.208% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -157.061% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -1331.695% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -51147.969% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 57.928% |
| Eyenovia, Inc. | 25.4 Million USD | -1190.96% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -133.75% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -5796.926% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -314.476% |
| Arcellx, Inc. | 200.19 Million USD | -63.83% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -614.569% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -51.557% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -3194.034% |
| Moolec Science SA | 52.75 Million USD | -521.769% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -436.47% |
| Geron Corporation | 70.44 Million USD | -365.619% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -604.742% |
| Royalty Pharma plc | 862.4 Million USD | 61.968% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -248.655% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -3416.206% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -1349.44% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -57.829% |
| Humacyte, Inc. | 23.49 Million USD | -1295.868% |
| Structure Therapeutics Inc. | 102.77 Million USD | -219.131% |
| 89bio, Inc. | 151.2 Million USD | -116.917% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -309.308% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -2155.757% |
| Genelux Corporation | 24.33 Million USD | -1247.799% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -866.857% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -89.732% |
| Notable Labs, Ltd. | 14.77 Million USD | -2120.63% |
| Liquidia Corporation | 87.98 Million USD | -272.78% |
| Mustang Bio, Inc. | 48.5 Million USD | -576.248% |
| Immunovant, Inc. | 282.7 Million USD | -16.016% |
| Quantum-Si incorporated | 111.65 Million USD | -193.74% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -1354.875% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -1442.234% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -221.518% |
| Acasti Pharma Inc. | 11.3 Million USD | -2802.283% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -1330.939% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1952.566% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -604.712% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -28808.23% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -1964.629% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -1024.9% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -692.545% |
| PepGen Inc. | 84.76 Million USD | -286.932% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -1006.905% |
| United Therapeutics Corporation | 885.1 Million USD | 62.944% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -1332.445% |
| Solid Biosciences Inc. | 104.31 Million USD | -214.42% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -902.236% |
| Immuneering Corporation | 58.41 Million USD | -461.498% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -6343.454% |
| Silo Pharma, Inc. | 3.92 Million USD | -8263.056% |
| Belite Bio, Inc | 31.66 Million USD | -935.705% |
| XOMA Corporation | 46.46 Million USD | -605.91% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -385.547% |
| Bionomics Limited | 17.89 Billion USD | 98.167% |
| Apogee Therapeutics, Inc. | 93 Million USD | -252.663% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 1019.246% |
| uniQure N.V. | 285.08 Million USD | -15.048% |
| Cassava Sciences, Inc. | 105.95 Million USD | -209.547% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -4386.766% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -68.885% |
| Forte Biosciences, Inc. | 32.47 Million USD | -909.906% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -3847.487% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -1015.792% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -5796.926% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -2208.142% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -3589.808% |
| Altimmune, Inc. | 30.55 Million USD | -973.396% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 23.305% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 1019.246% |
| Compugen Ltd. | 43.97 Million USD | -645.917% |
| Peak Bio, Inc. | 1249.13 USD | -26257135.036% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -342.508% |
| Benitec Biopharma Inc. | 22.38 Million USD | -1365.405% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -34.869% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -1049.098% |
| Zura Bio Limited | 62.63 Million USD | -423.623% |
| PolyPid Ltd. | 21.04 Million USD | -1458.503% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -1915.157% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -1049.098% |
| Instil Bio, Inc. | 85.78 Million USD | -282.336% |
| argenx SE | 1.53 Billion USD | 78.612% |
| Immunome, Inc. | 122.82 Million USD | -167.047% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -576.639% |
| Verona Pharma plc | 67.15 Million USD | -388.43% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -1167.093% |
| Shattuck Labs, Inc. | 93.61 Million USD | -250.361% |
| CervoMed Inc. | 14.95 Million USD | -2092.754% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -363.894% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -3738.799% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -543.112% |
| Moolec Science SA | 52.75 Million USD | -521.769% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -1894.031% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -147.434% |
| AnaptysBio, Inc. | 181.56 Million USD | -80.641% |
| Design Therapeutics, Inc. | 78.19 Million USD | -319.474% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -276.819% |
| NeurAxis, Inc. | 8.82 Million USD | -3618.168% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -2506.174% |
| Lumos Pharma, Inc. | 38.66 Million USD | -748.279% |
| Achilles Therapeutics plc | 75.25 Million USD | -335.834% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -1167.093% |
| 180 Life Sciences Corp. | 13.47 Million USD | -2333.589% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -1137.573% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -11082.703% |
| Nutriband Inc. | 5.73 Million USD | -5620.007% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -196.071% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -489.343% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -544.641% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -396.206% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -506.002% |
| Palisade Bio, Inc. | 13.32 Million USD | -2362.365% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -622.295% |
| Beam Therapeutics Inc. | 554.19 Million USD | 40.817% |
| Neurogene Inc. | 55.58 Million USD | -490.085% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -31.993% |
| AEON Biopharma, Inc. | 48.42 Million USD | -577.253% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -239.145% |
| Sesen Bio, Inc. | 78.38 Million USD | -318.452% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -292.662% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -2505.781% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 27.274% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -273.179% |
| Athira Pharma, Inc. | 125.46 Million USD | -161.415% |
| Vaccinex, Inc. | 23.45 Million USD | -1298.367% |
| HCW Biologics Inc. | 21.02 Million USD | -1459.799% |
| XOMA Corporation | 46.46 Million USD | -605.91% |
| Nektar Therapeutics | 190.9 Million USD | -71.808% |
| Arvinas, Inc. | 480 Million USD | 31.669% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -14323.541% |
| Merus N.V. | 200.49 Million USD | -63.589% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -217.34% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -847.392% |
| Rezolute, Inc. | 70.38 Million USD | -365.977% |
| Clene Inc. | 41.07 Million USD | -698.546% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -1902.549% |
| BeyondSpring Inc. | 24.86 Million USD | -1219.071% |
| Synlogic, Inc. | 58.53 Million USD | -460.355% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -1733.149% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -7201.581% |
| Peak Bio, Inc. | 1249.13 USD | -26257135.036% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -442.612% |
| Krystal Biotech, Inc. | 160.42 Million USD | -104.448% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -21.193% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 5.761% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -15107.578% |
| MannKind Corporation | 125.59 Million USD | -161.142% |
| Ikena Oncology, Inc. | 84.57 Million USD | -287.797% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -3299.886% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -266.053% |
| Gossamer Bio, Inc. | 183.75 Million USD | -78.488% |
| CohBar, Inc. | 12.38 Million USD | -2547.555% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -546.611% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -1089.134% |
| Legend Biotech Corporation | 583.14 Million USD | 43.755% |
| Mural Oncology plc | 192.07 Million USD | -70.763% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -388.461% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -1931.474% |
| Disc Medicine, Inc. | 91.12 Million USD | -259.931% |
| Champions Oncology, Inc. | 28.11 Million USD | -1066.798% |
| REGENXBIO Inc. | 321.15 Million USD | -2.127% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -6017.752% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -488.254% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -741.842% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -186.81% |
| Vaxart, Inc. | 90.72 Million USD | -261.514% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -3749.609% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -666.431% |
| Cellectis S.A. | 97.32 Million USD | -237.019% |
| Longeveron Inc. | 21.25 Million USD | -1443.468% |
| Repare Therapeutics Inc. | 167.35 Million USD | -95.98% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 75.898% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -333.587% |
| Revolution Medicines, Inc. | 498.76 Million USD | 34.24% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -4830.652% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -646.205% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -339.72% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -371.009% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -2865.524% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 93.131% |
| Denali Therapeutics Inc. | 527.23 Million USD | 37.791% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -3688.838% |
| Veru Inc. | 101.34 Million USD | -223.624% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -1301.235% |
| Cingulate Inc. | 22.75 Million USD | -1341.119% |
| Passage Bio, Inc. | 108.38 Million USD | -202.602% |
| Context Therapeutics Inc. | 25.07 Million USD | -1208.148% |
| Exicure, Inc. | 14.07 Million USD | -2230.115% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -59.168% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -657.458% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -3473.898% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -29.905% |
| Nuvalent, Inc. | 149.49 Million USD | -119.401% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -3965.836% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -216.437% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -1429.148% |
| OmniAb, Inc. | 83.89 Million USD | -290.949% |
| Anew Medical, Inc. | 1.3 Million USD | -25113.458% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -901.059% |
| Lipocine Inc. | 15.08 Million USD | -2074.96% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -378.722% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -330.7% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -713.575% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -185.596% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -1365.274% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 50.615% |
| Ocugen, Inc. | 71.56 Million USD | -358.294% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -249.42% |
| Q32 Bio Inc. | 92.68 Million USD | -253.892% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -1449.008% |
| Alumis Inc. Common Stock | 158.17 Million USD | -107.358% |
| Equillium, Inc. | 50.6 Million USD | -548.119% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -425.57% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -2258.676% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -1638.591% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -598.573% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -202.387% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -2546.609% |
| Dominari Holdings Inc. | 23.83 Million USD | -1276.073% |
| Edesa Biotech, Inc. | 9.22 Million USD | -3456.279% |
| vTv Therapeutics Inc. | 11.9 Million USD | -2654.573% |
| Bio-Techne Corporation | 563.03 Million USD | 41.747% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 19.77% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -22.039% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -147.955% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -2175.949% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -100.363% |
| Nkarta, Inc. | 131.65 Million USD | -149.136% |
| BioCardia, Inc. | 12.12 Million USD | -2605.94% |
| Iterum Therapeutics plc | 47.46 Million USD | -590.964% |